Overview

* Compass Q2 net loss widens to $19.9 mln from $13.1 mln last year

* Company ends Q2 with $101 mln cash, runway into 2027

* Tovecimig shows fewer deaths than projected in Phase 2/3 study

Outlook

* Company expects tovecimig secondary endpoint analysis in Q1 2026

* Compass plans CTX-8371 cohort expansions in Q4 2025

* Company to file IND for CTX-10726 in Q4 2025

* Compass anticipates cash runway into 2027

Result Drivers

* G&A - Increased by 20%, primarily due to $1.6 million in additional share-based compensation expense

* R&D - Expenses were $16.4 million for the quarter ended June 30, 2025, as compared to $11.2 million for the same period in 2024, an increase of $5.2 million, or 47%.

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Net -$19.88

Income mln

Q2 Basic -$0.14

EPS

Q2 -$21.07

Income mln

From

Operatio

ns

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Compass Therapeutics Inc. ( CMPX ) is $9.50, about 71.6% above its August 8 closing price of $2.70

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)